Alan Hb Wu

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Validation of the 99th percentile cutoff independent of assay imprecision (CV) for cardiac troponin monitoring for ruling out myocardial infarction
    Fred S Apple
    Hennepin County Medical Center and University of Minnesota School of Medicine, Minneapolis, 55415, USA
    Clin Chem 51:2198-200. 2005
  2. ncbi Integrated Biomarkers in Cardiovascular Disease - Third International Symposium
    Alan Wu
    University of California, San Francisco, CA 94110, USA
    IDrugs 11:636-8. 2008
  3. doi Biomarkers for cholesterol absorption and synthesis in hyperlipidemic patients: role for therapeutic selection
    Alan H B Wu
    Clinical Chemistry Laboratory, Department of Laboratory Medicine, San Francisco General Hospital, University of California, San Francisco, 1001 Potrero Avenue, San Francisco, CA 94110, USA Electronic address
    Clin Lab Med 34:157-66, viii. 2014
  4. doi Biological variation of β-sitosterol, campesterol, and lathosterol as cholesterol absorption and synthesis biomarkers
    Alan H B Wu
    Clinical Chemistry Laboratory, Department of Laboratory Medicine, San Francisco General Hospital, University of California, San Francisco, CA, United States Electronic address
    Clin Chim Acta 430:43-7. 2014
  5. doi Lack of impairment due to confirmed codeine use prior to a motor vehicle accident: role of pharmacogenomics
    Alan H B Wu
    Department of Laboratory Medicine, University of California, San Francisco, CA, USA Electronic address
    J Forensic Leg Med 20:1024-7. 2013
  6. ncbi Biological and analytical variation of clinical biomarker testing: implications for biomarker-guided therapy
    Alan H B Wu
    Department of Laboratory Medicine, University of California, San Francisco, San Francisco General Hospital, 1001 Potrero Ave, Room 2M27, San Francisco, CA, 94110, USA
    Curr Heart Fail Rep 10:434-40. 2013
  7. doi Genotype and phenotype concordance for pharmacogenetic tests through proficiency survey testing
    Alan H B Wu
    Department of Laboratory Medicine, University of California, San Francisco, USA
    Arch Pathol Lab Med 137:1232-6. 2013
  8. doi Analytical and assay issues for use of cardiac troponin testing for risk stratification in primary care
    Alan H B Wu
    Department of Laboratory Medicine, University of California, San Francisco, CA, USA
    Clin Biochem 46:969-78. 2013
  9. doi Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results
    Alan H B Wu
    Clinical Chemistry Laboratory, Department of Laboratory Medicine, San Francisco General Hospital, University of California, San Francisco, CA 94110, USA
    Am Heart J 165:995-9. 2013
  10. doi Implementation of liquid chromatography/mass spectrometry into the clinical laboratory
    Alan H B Wu
    Department of Laboratory Medicine, University of California, San Francisco, CA, United States
    Clin Chim Acta 420:4-10. 2013

Detail Information

Publications97

  1. ncbi Validation of the 99th percentile cutoff independent of assay imprecision (CV) for cardiac troponin monitoring for ruling out myocardial infarction
    Fred S Apple
    Hennepin County Medical Center and University of Minnesota School of Medicine, Minneapolis, 55415, USA
    Clin Chem 51:2198-200. 2005
  2. ncbi Integrated Biomarkers in Cardiovascular Disease - Third International Symposium
    Alan Wu
    University of California, San Francisco, CA 94110, USA
    IDrugs 11:636-8. 2008
  3. doi Biomarkers for cholesterol absorption and synthesis in hyperlipidemic patients: role for therapeutic selection
    Alan H B Wu
    Clinical Chemistry Laboratory, Department of Laboratory Medicine, San Francisco General Hospital, University of California, San Francisco, 1001 Potrero Avenue, San Francisco, CA 94110, USA Electronic address
    Clin Lab Med 34:157-66, viii. 2014
    ..Sterol-based biomarkers are available to assess the cause of hypercholesterolemia and may have an impact on therapeutic selection. ..
  4. doi Biological variation of β-sitosterol, campesterol, and lathosterol as cholesterol absorption and synthesis biomarkers
    Alan H B Wu
    Clinical Chemistry Laboratory, Department of Laboratory Medicine, San Francisco General Hospital, University of California, San Francisco, CA, United States Electronic address
    Clin Chim Acta 430:43-7. 2014
    ..The analysis of blood for β-sitosterol and campesterol is the measures of cholesterol absorption while lathosterol is a measure of cholesterol synthesis...
  5. doi Lack of impairment due to confirmed codeine use prior to a motor vehicle accident: role of pharmacogenomics
    Alan H B Wu
    Department of Laboratory Medicine, University of California, San Francisco, CA, USA Electronic address
    J Forensic Leg Med 20:1024-7. 2013
    ..We examined forensic serum toxicology and pharmacogenomics data from a woman on codeine shortly before she caused a motor vehicle accident...
  6. ncbi Biological and analytical variation of clinical biomarker testing: implications for biomarker-guided therapy
    Alan H B Wu
    Department of Laboratory Medicine, University of California, San Francisco, San Francisco General Hospital, 1001 Potrero Ave, Room 2M27, San Francisco, CA, 94110, USA
    Curr Heart Fail Rep 10:434-40. 2013
    ....
  7. doi Genotype and phenotype concordance for pharmacogenetic tests through proficiency survey testing
    Alan H B Wu
    Department of Laboratory Medicine, University of California, San Francisco, USA
    Arch Pathol Lab Med 137:1232-6. 2013
    ..Laboratories certified to perform pharmacogenetic testing must demonstrate successful performance on proficiency testing surveys...
  8. doi Analytical and assay issues for use of cardiac troponin testing for risk stratification in primary care
    Alan H B Wu
    Department of Laboratory Medicine, University of California, San Francisco, CA, USA
    Clin Biochem 46:969-78. 2013
    ..While these issues are directed to the use of troponin in primary care, most of these concepts are relevant to the use of troponin in acute coronary syndromes as well...
  9. doi Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results
    Alan H B Wu
    Clinical Chemistry Laboratory, Department of Laboratory Medicine, San Francisco General Hospital, University of California, San Francisco, CA 94110, USA
    Am Heart J 165:995-9. 2013
    ..Galectin-3 and soluble ST2 (sST2) are novel serum biomarkers of chronic heart failure...
  10. doi Implementation of liquid chromatography/mass spectrometry into the clinical laboratory
    Alan H B Wu
    Department of Laboratory Medicine, University of California, San Francisco, CA, United States
    Clin Chim Acta 420:4-10. 2013
    ..For certain clinical chemistry and toxicology analytes, liquid chromatography (LC) coupled with tandem mass spectrometry (MS/MS) offers significant advantages over traditional testing by immunoassay...
  11. ncbi The effect of diabetes on the diagnostic and prognostic performance of mid-region pro-atrial natriuretic peptide and mid-region pro-adrenomedullin in patients with acute dyspnea
    Alan H B Wu
    University of California, San Francisco, San Francisco, CA 94110, USA
    Biomarkers 17:490-7. 2012
    ..However, in patients without AHF, increased MR-proADM alone was associated with the presence of diabetes...
  12. doi Role of liquid chromatography-high-resolution mass spectrometry (LC-HR/MS) in clinical toxicology
    Alan Hb Wu
    Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA
    Clin Toxicol (Phila) 50:733-42. 2012
    ..Blood can be used in preference to urine which is more relevant to the patient's current clinical situation...
  13. doi Long-term biological variation in cardiac troponin I
    Alan H B Wu
    Department of Laboratory Medicine, University of California, San Francisco, CA, USA
    Clin Biochem 45:714-6. 2012
    ..To determine the long-term biological variation (BV) of cardiac troponin I...
  14. doi Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score
    Alan H B Wu
    Department of Laboratory Medicine, San Francisco General Hospital, San Francisco, CA 94110, USA
    Breast Cancer Res Treat 133:677-83. 2012
    ..If endoxifen levels are confirmed to be predictive of tamoxifen benefit, then this algorithm may be helpful to determine which women warrant endoxifen testing...
  15. pmc Gene expression profiles help identify the tissue of origin for metastatic brain cancers
    Alan H B Wu
    Department of Laboratory Medicine, University of California San Francisco, CA 94143, USA
    Diagn Pathol 5:26. 2010
    ..The purpose of this study was to evaluate the performance of the Tissue of Origin Test in the diagnosis of primary sites for metastatic brain cancer patients...
  16. ncbi Relationship of B-type natriuretic peptide and anemia in patients with and without heart failure: a substudy from the Breathing Not Properly (BNP) Multinational Study
    Alan H B Wu
    Department of Laboratory Medicine, University of California, San Francisco, San Francisco General Hospital, 1001 Potrero Ave, California 94110, USA
    Am J Hematol 80:174-80. 2005
    ..Among systolic HF patients, the presence of a low hemoglobin concentration is not a factor in the interpretation of BNP results...
  17. doi Interpretation of high sensitivity cardiac troponin I results: reference to biological variability in patients who present to the emergency room with chest pain: case report series
    Alan H B Wu
    Department of Laboratory Medicine, University of California, San Francisco, San Francisco General Hospital, San Francisco, CA 94110, United States
    Clin Chim Acta 401:170-4. 2009
    ..Cases are reported whereby the use of serial testing, the 99th percentile cutoff, and the application of biological variation of cTnI were used to help determine ischemic vs. non-ischemic causes of myocardial injury...
  18. ncbi State-wide hospital clinical laboratory plan for measuring cholinesterase activity for individuals suspected of exposure to nerve agent chemical weapons
    Alan H B Wu
    Department of Laboratory Medicine, University of California, San Francisco, CA 94110, USA
    Clin Toxicol (Phila) 46:110-6. 2008
    ..Hospital laboratories currently lack the capacity to provide emergency determination of cholinesterase activity...
  19. ncbi Early detection of acute coronary syndromes and risk stratification by multimarker analysis
    Alan Hb Wu
    University of California, Department of Laboratory Medicine, San Francisco, CA, USA
    Biomark Med 1:45-57. 2007
    ..Representative approaches include the Multimarker Index, classification and regression tree analysis and neural networks...
  20. doi Short- and long-term biological variation in cardiac troponin I measured with a high-sensitivity assay: implications for clinical practice
    Alan H B Wu
    Department of Laboratory Medicine, University of California, San Francisco General Hospital, San Francisco, CA 94110, USA
    Clin Chem 55:52-8. 2009
    ....
  21. doi Use of genetic and nongenetic factors in warfarin dosing algorithms
    Alan H B Wu
    University of California, San Francisco, Department of Laboratory Medicine, Clinical Chemistry Laboratory, San Francisco General Hospital, 1001 Potrero Avenue, San Francisco, CA 94110, USA
    Pharmacogenomics 8:851-61. 2007
    ..The development of a warfarin dosing algorithm that includes genotyping may be the means to achieve this goal...
  22. ncbi Plasma BNP/NT-proBNP assays: what do they target and what else might they recognize?
    Alan H B Wu
    University of California, San Francisco, CA, USA
    Heart Fail Clin 2:291-8. 2006
  23. ncbi Development and preliminary clinical validation of a high sensitivity assay for cardiac troponin using a capillary flow (single molecule) fluorescence detector
    Alan H B Wu
    University of California, San Francisco, CA, USA
    Clin Chem 52:2157-9. 2006
  24. ncbi A selected history and future of immunoassay development and applications in clinical chemistry
    Alan H B Wu
    Department of Laboratory Medicine, University of California, San Francisco, Clinical Chemistry Laboratory, San Francisco General Hospital, San Francisco, CA 94110, USA
    Clin Chim Acta 369:119-24. 2006
    ..The first immunoassay was described by Berson and Yalow in 1959. Their work resulted in their receipt of the Nobel Prize in Medicine in 1977. Since this introduction, immunoassays have evolved considerably...
  25. doi Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations
    Alan H B Wu
    University of California, Department of Laboratory Medicine, Clinical Chemistry Laboratory, San Francisco General Hospital, 1001 Potrero Ave, San Francisco, CA 94110, USA
    Pharmacogenomics 9:169-78. 2008
    ..We developed and validated a warfarin-dosing algorithm for a multi-ethnic population that predicts the best dose for stable anticoagulation, and compared its performance against other regression equations...
  26. doi The clinical need for high-sensitivity cardiac troponin assays for acute coronary syndromes and the role for serial testing
    Alan H B Wu
    Department of Laboratory Medicine, Clinical Chemistry Laboratory, San Francisco General Hospital, University of California, San Francisco, CA 94110, USA
    Am Heart J 155:208-14. 2008
    ..Therefore, there is a need to develop troponin assays with higher sensitivity, which cannot be achieved while also improving the assay's precision...
  27. ncbi The effect of diabetes on B-type natriuretic peptide concentrations in patients with acute dyspnea: an analysis from the Breathing Not Properly Multinational Study
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, Connecticut, USA
    Diabetes Care 27:2398-404. 2004
    ..We determined the effect of diabetes on B-type natriuretic peptide (BNP) concentrations in patients presenting to the emergency department with dyspnea...
  28. doi Limitations of point-of-care testing in the ED or ICU: a role for regional centralized toxicology laboratories
    A H B Wu
    Department of Laboratory Medicine, University of California, San Francisco, and Clinical Chemistry and Toxicology Laboratories, San Francisco General Hospital, San Francisco, California, USA
    Clin Pharmacol Ther 88:295-8. 2010
    ..Therefore, a regional toxicology laboratory using liquid chromatography-mass spectrometry is desirable for accurate and comprehensive coverage of drug testing...
  29. ncbi Antiquated tests within the clinical pathology laboratory
    Alan H B Wu
    Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94110, USA
    Am J Manag Care 16:e220-7. 2010
    ..To provide evidence supporting the discontinuation of laboratory tests that do not have clinical utility today...
  30. pmc Drug metabolizing enzyme activities versus genetic variances for drug of clinical pharmacogenomic relevance
    Alan Hb Wu
    Department of Laboratory Medicine, University of California, San Francisco, San Francisco General Hospital, 1001 Potrero, San Francisco CA 94110, USA
    Clin Proteomics 8:12. 2011
    ..Other tests where there is considerable data but have not been widely implemented includes CYP 2C9 for warfarin, CYP 2D6 for tamoxifen and codeine, and CYP 2C19 for the proton pump inhibitors...
  31. ncbi Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, Hartford, Connecticut 06102, USA
    Am J Cardiol 92:628-31. 2003
    ..This study also shows that there are important differences in the performance of BNP versus NT-proBNP in monitoring patients with congestive heart failure that need to be further explored...
  32. ncbi Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study
    Alan S Maisel
    University of California, San Diego, Veteran s Affairs Medical Center, San Diego, Calif 92161, USA
    Am Heart J 147:1078-84. 2004
    ..B-type natriuretic peptide (BNP) is secreted from the cardiac ventricles in response to increased wall tension...
  33. ncbi B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study
    Peter A McCullough
    University of California, San Diego Veteran s Affairs Medical Center, San Diego, CA, USA
    Am J Kidney Dis 41:571-9. 2003
    ..However, relationships between BNP, renal function, and heart failure as an emergency diagnosis are unknown...
  34. ncbi How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study
    Lori B Daniels
    University of California, San Diego, CA, USA
    Am Heart J 151:999-1005. 2006
    ..We evaluated differential cut-points for BNP in diagnosing acute HF across body mass index levels to determine whether alternative cut-points can improve diagnosis...
  35. ncbi Impact of the history of congestive heart failure on the utility of B-type natriuretic peptide in the emergency diagnosis of heart failure: results from the Breathing Not Properly Multinational Study
    Adam Strunk
    University of California, San Diego, Veterans Affairs San Diego Healthcare System, San Diego, Calif 92161, USA
    Am J Med 119:69.e1-11. 2006
    ..We hypothesized that taking into account the history of congestive heart failure along with other clinical variables would be helpful in this range of B-type natriuretic peptide levels...
  36. ncbi Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure
    Alan S Maisel
    University of California, San Diego, Veterans Affairs Medical Center, San Diego 92161, USA
    N Engl J Med 347:161-7. 2002
    ..B-type natriuretic peptide is released from the cardiac ventricles in response to increased wall tension...
  37. ncbi Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, 80 Seymour St, Hartford, CT 06102, USA
    Eur J Heart Fail 6:355-8. 2004
    ..From these studies, the percent statistical change in serial samples of approximately 100% difference was estimated (95% confidence)...
  38. ncbi The role of cardiac troponin in the recent redefinition of acute myocardial infarction
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, 80 Seymour St, Hartford, CT 06102, USA
    Clin Lab Sci 17:50-2. 2004
  39. ncbi Cardiac markers: cost-effective triage for MI admission and therapy
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, Hartford, CT, USA
    MLO Med Lab Obs 34:36-40. 2002
  40. ncbi Predictors of elevated B-type natriuretic peptide concentrations in dyspneic patients without heart failure: an analysis from the breathing not properly multinational study
    Cathrine W Knudsen
    University of California, San Diego, Veteran s Affairs Medical Center, San Diego, CA, USA
    Ann Emerg Med 45:573-80. 2005
    ..The objective of the current study was to identify independent predictors of elevated BNP concentrations in the absence of congestive heart failure...
  41. pmc N-terminal pro-B-type natriuretic peptide as a diagnostic test for ventricular dysfunction in patients with coronary disease: data from the heart and soul study
    David C M Corteville
    Department of Medicine, University of California, San Francisco, CA, USA
    Arch Intern Med 167:483-9. 2007
    ..Whether NT-proBNP can be used to detect ventricular dysfunction in patients with stable coronary heart disease (CHD) and no history of heart failure is unknown...
  42. pmc Performance evaluation of three liquid chromatography mass spectrometry methods for broad spectrum drug screening
    Kara L Lynch
    Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA
    Clin Chim Acta 411:1474-81. 2010
    ..This study was designed to characterize the sensitivity and specificity of three LC-MS(/MS) vendor-supplied methods for targeted CDS and identify the current limitations associated with the use of these technologies...
  43. ncbi Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results
    Alan H B Wu
    Clinical Chemistry Laboratory, Department of Laboratory Medicine, San Francisco General Hospital, University of California, San Francisco, CA 94110, USA
    Am Heart J 152:828-34. 2006
    ..An assessment of the analytical and biologic variations is necessary to interpret the results of serial testing...
  44. doi Vitamin D status of county hospital patients assessed by the DiaSorin LIAISON® 25-hydroxyvitamin D assay
    Deborah French
    Department of Laboratory Medicine, University of California San Francisco San Francisco General Hospital, San Francisco, CA 94110, USA
    Clin Chim Acta 412:258-62. 2011
    ..Due to the increased interest in vitamin D, there has been an exponential increase in the number of clinicians testing their patients and therefore also in the volume of this test run in clinical laboratories...
  45. pmc Prevalence of smoking assessed biochemically in an urban public hospital: a rationale for routine cotinine screening
    Neal L Benowitz
    Division of Clinical Pharmacology and Experimental Therapeutics, University of California San Francisco, San Francisco, CA 94143 1220, USA
    Am J Epidemiol 170:885-91. 2009
    ....
  46. pmc N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease
    Kirsten Bibbins-Domingo
    Department of Medicine, University of California, San Francisco, CA 94143, USA
    JAMA 297:169-76. 2007
    ..Identification of individuals at high risk for cardiovascular events is important for the optimal use of primary and secondary prevention measures...
  47. ncbi A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation
    Stacey J Wieczorek
    Department of Pathology and Laboratory Medicine, Hartford Hospital, Hartford, Conn, USA
    Am Heart J 144:834-9. 2002
    ....
  48. ncbi B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study
    Peter A McCullough
    University of California, Veteran s Affairs Medical Center, San Diego, USA
    Circulation 106:416-22. 2002
    ..We sought to determine the degree to which B-type natriuretic peptide (BNP) adds to clinical judgment in the diagnosis of congestive heart failure (CHF)...
  49. ncbi National academy of clinical biochemistry laboratory medicine practice guidelines: recommendations for the use of laboratory tests to support poisoned patients who present to the emergency department
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, Hartford, CT 06102, USA
    Clin Chem 49:357-79. 2003
    ..Exposure to drugs and toxins is a major cause for patients' visits to the emergency department (ED)...
  50. ncbi National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure
    Alan H B Wu
    University of California at San Francisco, San Francisco, CA, USA
    Clin Chem 53:2086-96. 2007
  51. ncbi Evaluation of a point-of-care assay for cardiac markers for patients suspected of acute myocardial infarction
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, 80 Seymour St, Hartford, CT 06102, USA
    Clin Chim Acta 346:211-9. 2004
    ..With new rapid ED assessment protocols, there is increasing pressure to produce results with a short turnaround time (TAT), and point-of-care (POC) testing is one alternative for providing fast results...
  52. ncbi Reduced readmission rate for alternating diagnoses of heart failure and pulmonary disease after implementation of B-type natriuretic peptide testing
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, 80 Seymour St, Hartford, CT 06102, USA
    Eur J Heart Fail 6:309-12. 2004
    ..Effective disease management requires an accurate diagnosis. B-type natriuretic peptide (BNP) is increased in patients with HF and is normal in PD patients without cardiac involvement...
  53. doi Interpretation of creatine kinase and aldolase for statin-induced myopathy: Reliance on serial testing based on biological variation
    Alan H B Wu
    Department of Laboratory Medicine, University of California, San Francisco, CA, USA
    Clin Chim Acta 399:109-11. 2009
    ..Therefore, serial testing relative to baseline levels may be more effective in detecting mild increases in CK...
  54. pmc Prevalence and prognostic significance of incidental cardiac troponin T elevation in ambulatory patients with stable coronary artery disease: data from the Heart and Soul study
    Bill P C Hsieh
    Division of Cardiology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
    Am Heart J 158:673-9. 2009
    ..We sought to investigate the prevalence and prognostic value of cardiac troponin T (cTnT) elevation in a population with stable CAD...
  55. ncbi Correlation of B-type natriuretic peptide level to 6-min walk test performance in patients with left ventricular systolic dysfunction
    Stacey J Wieczorek
    Department of Pathology and Laboratory Medicine, Hartford Hospital, 80 Seymour St, Hartford, CT 06102, USA
    Clin Chim Acta 328:87-90. 2003
    ..We compared whole blood BNP concentrations to distance walked during a 6-min walk test in patients with CHF...
  56. ncbi Cardiovascular predictors of in-patient mortality after subarachnoid hemorrhage
    Sirisha Yarlagadda
    Department of Medicine, University of California San Francisco, San Francisco, CA 94143 0124, USA
    Neurocrit Care 5:102-7. 2006
    ..The objective of this study was to test the hypothesis that cardiovascular abnormalities are independently related to in-patient mortality after SAH...
  57. ncbi Long-term follow-up of patients with increased cardiac troponin concentrations following percutaneous coronary intervention
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford, Connecticut 06102, USA
    Am J Cardiol 89:1300-2. 2002
  58. ncbi Markers for early detection of cardiac diseases
    Alan H B Wu
    Department of Laboratory Medicine University of California, San Francisco, CA, USA
    Scand J Clin Lab Invest Suppl 240:112-21. 2005
    ..Each of these tests has demonstrated some utility for early diagnosis. However, as most lack specificity for myocardial disease, routine use may require a multi-marker approach...
  59. ncbi A 24-hour comparison of serum growth hormone concentrations in patients with heart failure versus healthy controls
    Brett Duncan
    Division of Cardiology, Hartford Hospital, Hartford, Connecticut 06102 5037, USA
    Pharmacotherapy 23:147-52. 2003
    ..To compare endogenous serum growth hormone concentrations over a 24-hour period in patients with chronic heart failure (CHF) and matched controls...
  60. doi Clinical utility of an LC-MS/MS seizure panel for common drugs involved in drug-induced seizures
    Julia C Drees
    Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA
    Clin Chem 55:126-33. 2009
    ..We investigated whether results from a seizure panel using LC-MS/MS could affect patient care...
  61. ncbi Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, 80 Seymour St, Hartford, CT 06102, USA
    Clin Chem 50:867-73. 2004
    ..B-Type natriuretic peptide (BNP) is released from the left ventricle of the heart into the circulation in response to ventricular stretching and volume overload. Increased BNP concentrations are associated with heart failure (HF)...
  62. pmc Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment
    Wendy Lorizio
    Division of General Internal Medicine, Department of Medicine, University of California San Francisco, 1545 Divisadero Street, Suite 322, San Francisco, CA 94143 0320, USA
    Genome Med 3:64. 2011
    ..We evaluated the effect of CYP2D6 testing in clinical practice to determine whether genotype results affected choice of hormone therapy in a prospective cohort study...
  63. ncbi Diminished need for folate measurements among indigent populations in the post folic acid supplementation era
    Dean W Joelson
    University of California, San Francisco, Department of Laboratory Medicine, San Francisco, CA 94110, USA
    Arch Pathol Lab Med 131:477-80. 2007
    ..The incidence of folate deficiency in most populations has declined dramatically since then...
  64. ncbi Signify ER Drug Screen Test evaluation: comparison to Triage Drug of Abuse Panel plus tricyclic antidepressants
    Jane Ellen Phillips
    University of North Carolina Hospitals, McLendon Clinical Labs, Department of Pathology and Laboratory Medicine, 101 Manning Drive, Chapel Hill, NC 27514, USA
    Clin Chim Acta 328:31-8. 2003
    ..In terms of operating characteristics, the Signify ER device is simpler since only a single pipetting step is required, and reaction completed within 8 min...
  65. ncbi Optimum blood collection intervals for B-type natriuretic peptide testing in patients with heart failure
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, Hartford, Connecticut 06102, USA
    Am J Cardiol 93:1562-3. 2004
    ..Samples collected 7 days apart were associated with the highest frequency (50%) of statistically different results (increased or decreased) compared with daily collections, where increased or decreased results occurred less often (22%)...
  66. doi Morbidity involving the hallucinogenic designer amines MDA and 2C-I
    Julia C Drees
    Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA
    J Forensic Sci 54:1485-7. 2009
    ..This report demonstrates the utility of testing for a wider menu of compounds using LC-MS/MS in order to better characterize the prevalence and toxicities of novel amines such as 2C-I...
  67. ncbi Quality specifications in thyroid diseases
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, 80 Seymour St, Hartford, CT 06102, USA
    Clin Chim Acta 346:73-7. 2004
    ..Given the importance of these measurements, quality specifications are needed to ensure accurate results. Goals for precision and accuracy are available based on known intraindividual and interindividual biological variation...
  68. ncbi The ischemia-modified albumin biomarker for myocardial ischemia
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, Hartford, CT, USA
    MLO Med Lab Obs 35:36-8, 40. 2003
    ..This area of clinical research will continue to grow, given the importance of detecting myocardial ischemia. Which marker or combination of markers will, ultimately, be the best approach awaits further research...
  69. pmc A hydrophilic-interaction chromatography tandem mass spectrometry method for quantitation of serum s-adenosylmethionine in patients infected with human immunodeficiency virus
    Ping Wang
    Department of Lab Medicine, University of California, San Francisco, CA, United States
    Clin Chim Acta 396:86-8. 2008
    ..In this study, we report a robust hydrophilic-interaction liquid chromatography tandem mass spectrometry (LC-MS/MS) assay that can be used to quantitate serum SAM in clinical laboratories...
  70. ncbi Incomplete recovery of prescription opioids in urine using enzymatic hydrolysis of glucuronide metabolites
    Ping Wang
    Clinical Laboratories, San Francisco General Hospital, Department of Laboratory Medicine, University of California at San Francisco, San Francisco, California 94110, USA
    J Anal Toxicol 30:570-5. 2006
    ..We conclude that acid hydrolysis is the method of choice for GC-MS confirmation of urine opioids...
  71. doi Cardiac troponin and outcome in acute heart failure
    W Frank Peacock
    Department of Emergency Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    N Engl J Med 358:2117-26. 2008
    ..The purpose of our study was to describe the association between elevated cardiac troponin levels and adverse events in hospitalized patients with acute decompensated heart failure...
  72. ncbi Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study
    Alan S Maisel
    Cardiology 111 A, San Diego VA Medical Center, 3350 La Jolla Village Drive, San Diego, CA 92161, USA
    J Am Coll Cardiol 41:2010-7. 2003
    ..This study examines B-type natriuretic peptide (BNP) levels in patients with systolic versus non-systolic dysfunction presenting with shortness of breath...
  73. ncbi Diagnostic value of B-Type natriuretic peptide and chest radiographic findings in patients with acute dyspnea
    Cathrine W Knudsen
    Ulleval University Hospital, Oslo, Norway
    Am J Med 116:363-8. 2004
    ..To compare chest radiographic findings and circulating B-type natriuretic peptide (BNP) levels as an adjunct to clinical findings in the diagnosis of heart failure in patients presenting with acute dyspnea...
  74. ncbi National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biochemical markers of acute coronary syndromes
    Fred S Apple
    Clin Chem 53:547-51. 2007
  75. ncbi Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay
    Kiang Teck J Yeo
    Department of Pathology, Dartmouth Medical School and Dartmouth Hitchcock Medical Center, 1 Medical Center Drive, Lebanon, NH 03756, USA
    Clin Chim Acta 338:107-15. 2003
    ..Brain natriuretic peptides (BNPs) are useful in the assessment of heart failure, left ventricular dysfunction, and acute coronary syndromes...
  76. ncbi Prognostic value of the Ortho Vitros cardiac troponin I assay in patients with symptoms of myocardial ischemia. Risk stratification using European Society of Cardiology/American College of Cardiology recommended cutoff values
    Fred S Apple
    Department of Laboratory Medicine and Pathology, Hennepin County Medical Center, University of Minnesota School of Medicine, Minneapolis, USA
    Am J Clin Pathol 120:114-20. 2003
    ..08 microgram/L) group for cTnI, with directionally similar results for cTnT. Our findings validate the Ortho cTnI assay as a risk stratification biomarker in patients with symptoms of myocardial ischemia...
  77. ncbi National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical issues for biochemical markers of acute coronary syndromes
    Fred S Apple
    Hennepin County Medical Center, Minneapolis, MN, USA
    Circulation 115:e352-5. 2007
  78. ncbi Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study
    James L Januzzi
    Department of Medicine and Laboratory Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Am Coll Cardiol 50:607-13. 2007
    ..The aim of this study was to examine the value of measurement of the interleukin-1 receptor family member ST2 in patients with dyspnea...
  79. ncbi Multi-center validation of the Response Biomedical Corporation RAMP NT-proBNP assay with comparison to the Roche Diagnostics GmbH Elecsys proBNP assay
    Elizabeth Lee-Lewandrowski
    Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Clin Chim Acta 386:20-4. 2007
    ..Point-of-care (POC) assays may provide more timely results and potentially improve patient outcomes...
  80. ncbi National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine practice guidelines: Analytical issues for biomarkers of heart failure
    Fred S Apple
    Hennepin County Medical Center, Minneapolis, Minn, USA
    Circulation 116:e95-8. 2007
  81. ncbi European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: how to use existing assays clinically and for clinical trials
    Fred S Apple
    Department of Laboratory Medicine and Pathology, Hennepin County Medical Center and University of Minnesota School of Medicine, Minneapolis, Minn, USA
    Am Heart J 144:981-6. 2002
    ..The Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation (COURAGE) trial asked for recommendations concerning the use of troponin assays for the trial...
  82. ncbi National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure
    W H Wilson Tang
    Circulation 116:e99-109. 2007
  83. ncbi Association between anaemia and N-terminal pro-B-type natriuretic peptide (NT-proBNP): findings from the Heart and Soul Study
    Arati S Desai
    Department of Medicine, Johns Hopkins University, United States
    Eur J Heart Fail 9:886-91. 2007
    ..Anaemia is associated with elevated levels of natriuretic peptides. Whether the association of anaemia with natriuretic peptides is independent of other cardiovascular risk factors is unclear...
  84. ncbi National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure
    W H Wilson Tang
    Cleveland Clinic, Foundation, Cleveland, OH, USA
    Clin Biochem 41:210-21. 2008
  85. ncbi Reflex testing III: efficient use of laboratory markers for anemia
    Alan H B Wu
    Clin Chim Acta 343:241-3. 2004
  86. doi Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage
    Kristin N Luckenbill
    Clin Chem 54:619-21. 2008
  87. ncbi When the drug of choice is a drug of confusion: embalming fluid use in inner city Hartford, CT
    Merrill Singer
    Center for Community Health Research of the Hispanic Health Council, Hartford, CT 06106, USA
    J Ethn Subst Abuse 4:73-96. 2005
    ..The public health implications of this new wave of PCP use are assessed...
  88. ncbi B-type natriuretic peptide levels in patients in the emergency department with possible heart failure and previous stable angina pectoris and/or healed myocardial infarction
    James McCord
    Henry Ford Health System, Detroit, Michigan, USA
    Am J Cardiol 96:1370-3. 2005
    ..However, in patients who did not have heart failure, there was a relation between BNP levels and previous stable angina pectoris and/or healed myocardial infarction but no significant independent relation in multiple regression analysis...
  89. ncbi Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients: an analysis from the breathing not properly multinational study
    Cathrine Wold Knudsen
    Ulleval University Hospital, Oslo, Norway
    J Am Coll Cardiol 46:838-44. 2005
    ....
  90. ncbi National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes
    David A Morrow
    Clin Chem 53:552-74. 2007
  91. ncbi National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes
    David A Morrow
    Brigham and Women s Hospital, Harvard University, Boston, MA, USA
    Circulation 115:e356-75. 2007
  92. ncbi Comparative sensitivities between different plasma B-type natriuretic peptide assays in patients with minimally symptomatic heart failure
    W H Wilson Tang
    Department of Cardiovascular Medicine, Section of Heart Failure and Cardiac Transplantation Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Clin Cornerstone 7:S18-24. 2005
    ..These findings suggest that there is a relationship between the decision statistics used in screening for left ventricular dysfunction and the type of diagnostic assay used...
  93. ncbi Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome
    Fred S Apple
    Department of Laboratory Medicine and Pathology, Clinical Laboratories, Hennepin County Medical Center, Minneapolis, MN 55415, USA
    Clin Chem 51:810-24. 2005
    ....
  94. ncbi Quality specifications for B-type natriuretic peptide assays
    Fred S Apple
    Department of Laboratory Medicine and Pathology, Hennepin County Medical Center, Minneapolis, MN 55415, USA
    Clin Chem 51:486-93. 2005
    ....
  95. ncbi Influence of imprecision on ROC curve analysis for cardiac markers
    Peter Kupchak
    Nanogen, Point of Care Diagnostics Division, Toronto, Ontario, Canada
    Clin Chem 52:752-3. 2006
    ..There has been considerable debate regarding the impact of assay imprecision on the performance of cardiac biomarkers for diagnosis of acute coronary syndromes (ACS) and risk stratification for future adverse cardiac events...
  96. ncbi Multicenter evaluation of an automated assay for troponin I
    Denise Uettwiller-Geiger
    John T Mather Memorial Hospital, Port Jefferson, NY 11777, USA
    Clin Chem 48:869-76. 2002
    ..We describe an assay that overcomes problems of early assays that were often affected by cTnI degradation, assay interference, poor sensitivity, and imprecision...
  97. ncbi Evaluation of imprecision for cardiac troponin assays at low-range concentrations
    Mauro Panteghini
    Laboratorio Analisi Chimico Cliniche 1, Azienda Ospedaliera Spedali Civili, 25125 Brescia, Italy
    Clin Chem 50:327-32. 2004
    ..Pools of human sera containing cardiac troponin concentrations around the MI decision limit were assessed to identify the lowest concentration associated with a 10% CV...